C4 Therapeutics Nears Key Clinical Trial Milestones

C4 Therapeutics prepares to launch pivotal Phase 2 and Phase 1b trials for cemsidomide in multiple myeloma in 2026, marking a critical test of its ambitious 2028 roadmap.

The biopharmaceutical firm C4 Therapeutics is poised to enter a pivotal period in its development strategy, with the imminent launch of crucial clinical studies for its lead candidate, cemsidomide. The company's ambitious roadmap, targeting significant milestones through 2028, now faces a practical test as it prepares to initiate these trials.

Upcoming Clinical Catalysts

The immediate focus for C4 Therapeutics is the advancement of cemsidomide for multiple myeloma. A significant Phase 2 trial, named MOMENTUM, is scheduled to commence before the end of the first quarter of 2026. This study will evaluate cemsidomide in combination with dexamethasone.

Following closely, a Phase 1b combination study pairing cemsidomide with elranatamab is set to begin in the second quarter of the same year. These back-to-back clinical initiations represent the most critical near-term events for the company's pipeline and are expected to be primary drivers of its operational narrative in the coming months.

Broadening the Therapeutic Pipeline

Looking beyond its core oncology programs, C4 Therapeutics intends to leverage its Degronimid platform for applications in new disease areas. The company has outlined a goal to submit up to three Investigational New Drug (IND) applications by 2028, targeting neurodegenerative and inflammatory conditions.

A cornerstone of its business model remains strategic collaboration with major pharmaceutical partners. Existing alliances with industry leaders including Merck KGaA, Roche, and Biogen provide C4 Therapeutics with access to complementary expertise and resources, which are deemed vital for sustaining its long-term research and development efforts.

Measuring Progress

The official launch of the MOMENTUM study in the coming weeks will be the next visible step for investors. The progression and eventual results from this Phase 2 trial, coupled with the timely initiation of the combination study in Q2 2026, will serve as tangible benchmarks for assessing the company's execution against its stated timeline. The coming year is therefore set to provide clear data points on whether C4 Therapeutics can maintain its ambitious schedule leading to 2028.